"The voice for cancer physicians and their patients in Massachusetts."
The U.S. Food and Drug Administration approved nivolumab (OPDIVO, Bristol-Myers Squibb Co.) for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. Read full press release.
© Copyright. All rights reserved.
Massachusetts Society of Clinical Oncologists
P.O. Box 549154, Waltham, MA, 02454 Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org
